about
High-scatter T cells: a reliable biomarker for malignant T cells in cutaneous T-cell lymphoma.Combinatorial Screening Identifies Novel Promiscuous Matrix Metalloproteinase Activities that Lead to Inhibition of the Therapeutic Target IL-13.Immunoglobulin free light chains in adult atopic dermatitis patients do not correlate with disease severity.Biomarkers for atopic dermatitis: a systematic review and meta-analysis.Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis.Current and Future Biomarkers in Atopic Dermatitis.The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapies.Risk of Non-melanoma Skin Cancer in Patients with Atopic Dermatitis Treated with Oral Immunosuppressive Drugs.Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization.CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-γ, IL-13, IL-17, and IL-22.Cyclosporin A reduces CD4(+)CD25(+) regulatory T-cell numbers in patients with atopic dermatitis.[A woman with hyperpigmentations on the upper legs].Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis.Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis.Allopurinol Co-prescription Improves the Outcome of Azathioprine Treatment in Chronic Eczema.Serum biomarker profiles suggest that atopic dermatitis is a systemic disease.Atopic dermatitis: A tale of two distinct pathomechanisms that make you itch.Differential expression of genes involved in skin homing, proliferation, and apoptosis in CD4+ T cells of patients with atopic dermatitis.Epicutaneous application of house dust mite induces thymic stromal lymphopoietin in nonlesional skin of patients with atopic dermatitis.EASI p-EASI: predicting disease severity in atopic dermatitis patients treated with Cyclosporin AAbsence of T-regulatory cell expression and function in atopic dermatitis skinPD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammationAtherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary arteryInflammation of the atherosclerotic cap and shoulder of the plaque is a common and locally observed feature in unruptured plaques of femoral and coronary arteriesEfficacy and safety of long-term treatment with cyclosporin A for atopic dermatitisCyclosporin A treatment is associated with increased serum immunoglobulin E levels in a subgroup of atopic dermatitis patientsGene expression in CD4+ T-cells reflects heterogeneity in infant wheezing phenotypesModulation of lymphocyte function in vivo via inhibition of calcineurin or purine synthesis in patients with atopic dermatitisUtility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severityBrief report: enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluidA panel of biomarkers for disease severity in atopic dermatitisFirst experience with extended release tacrolimus in the treatment of adult patients with severe, difficult to treat atopic dermatitis: Clinical efficacy, safety and dose findingMultiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitisPredicting therapy response to mycophenolic acid using UGT1A9 genotyping: towards personalized medicine in atopic dermatitisEASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patientsBiomarkers detected in dried blood spots from atopic dermatitis patients strongly correlate with disease severityClinical and histopathological characterization of paradoxical head and neck erythema in patients with atopic dermatitis treated with dupilumab: a case seriesAcute arthritis and arthralgia as an adverse drug reaction to dupilumab'En route' to precision medicineEffectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data
P50
Q34667769-04A368D8-A93B-44A7-9FA5-9E0873BAE52FQ35835394-7AD7A60C-7BC2-417A-A9C7-F41D0F21F683Q37476900-18AAA58A-2B93-4A85-8D63-859FD1A28C2FQ38557542-E183A5F4-9141-44EB-86F5-199D1474EE8DQ38730017-57BC9217-A2F8-40A2-A122-C67E47DF780AQ38790751-63964812-F7B4-4E7F-8317-E2689E63D2EEQ38805996-F8BF5D09-8A94-4694-AFDB-322871F3C1F7Q38952011-759D6E02-2F42-479A-8262-BD2F4DF931A1Q39765588-AA319A74-12DA-4105-B1CB-3E90F646650AQ42874986-6FF82D21-9A54-4A59-9277-D8FC3F3BC49EQ43274049-6B291390-5F7B-4181-851B-BE063C4E3D79Q44474203-FAB2F9CC-09C8-40D9-9215-9183F6AE3183Q44758838-7872FCA3-FE23-4C5E-8BB5-3DB59A8D086DQ46424938-166E4AB1-4640-4E3A-BF97-51BBFA0D1A6CQ50026156-6478A95B-82DE-43F8-ACA0-CFC34AC91328Q50149086-715F1C3F-9E23-4294-8D2D-4FA0E0915C3CQ51345023-3D0191E8-0D40-42BC-9291-9D5853BFEB62Q54626878-9E4A62F7-F579-4E1B-8C96-870BF1B99F3BQ54789505-512F785B-9ED9-4429-BD89-11EF8D2DBCEFQ58108008-C410EF28-EFCB-4CDC-95ED-4EF6FFEBF20DQ61703521-105575CF-F6D2-4B0C-AB22-ABADB4601C52Q63804697-29669CD6-3981-4D38-9C89-AB010D6D7068Q73901878-B7416E32-1897-4EEF-9C42-96EA251DAA71Q77795523-341CFAD9-A9AB-4FE4-9991-4A33BFE8F8CDQ79504557-921B1AB2-A213-498B-AC56-63F5721C1F1BQ80859940-3611FFC0-0708-4DAB-A33F-53846FE34C6AQ81611650-6CC08F97-4904-4962-A092-6395D50D824CQ84203565-BFFB7258-BF23-483B-ACAB-06169D94F95DQ85271479-2D5A4F0B-BF86-4C0B-887A-C8DD0423EA01Q85517802-05744C4B-4755-486D-962D-37733D1588E1Q86555452-7757D42E-2581-46F3-9BC2-3F2FCC498F77Q86646027-16BC2CD3-D1F3-4304-AC23-708AA89F99C2Q87667125-0386276C-D032-4067-9B04-C39E7DD5C253Q88176860-0319D61B-D475-4F7C-A780-CC4700CC6C3BQ88814022-4EC9E289-F8B2-47DB-B583-12B41E4B0C09Q90261375-F5A15560-FA62-4312-BC84-C25F366CF507Q91364549-44AA250B-05FF-48DE-8BE4-6D7CECBD10B4Q92022219-066A2342-E029-46D9-8F5A-11F66BE32833Q92033464-E90F9218-95BC-4AFB-ACC0-CC5A27D71468Q92404666-1FAE4FA4-210F-4228-8F65-CB282AAEED7F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Dirkjan Hijnen
@ast
Dirkjan Hijnen
@en
Dirkjan Hijnen
@es
Dirkjan Hijnen
@nl
type
label
Dirkjan Hijnen
@ast
Dirkjan Hijnen
@en
Dirkjan Hijnen
@es
Dirkjan Hijnen
@nl
prefLabel
Dirkjan Hijnen
@ast
Dirkjan Hijnen
@en
Dirkjan Hijnen
@es
Dirkjan Hijnen
@nl
P106
P1153
56201854200
P31
P496
0000-0003-3379-3425